Medtronic FY26 net income rises 3% to $4.8 billion; net sales increase 8% to $36.36 billion
Medtronic Plc
Medtronic Plc MDT | 0.00 |
- Medtronic fiscal 2026 net income attributable to shareholders rose 3% to $4.8 billion; diluted EPS increased 3% to $3.73.
- Net sales climbed 8% to $36.36 billion; operating cash flow increased 4% to $7.33 billion.
- Income tax provision rose to $1.3 billion; effective tax rate widened 4.6 percentage points to 21.2%.
- Cardiovascular net sales increased 12% to $13.98 billion; Cardiac Rhythm & Heart Failure jumped 17% to $7.5 billion.
- Diabetes net sales rose 13% to $3.11 billion; separation advanced with MiniMed IPO, leaving Medtronic with about 90.03% ownership.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-044354), on June 18, 2026, and is solely responsible for the information contained therein.
